Good News for Maintenance Therapies in IBD

Miguel Regueiro, MD

Professor of Medicine
Chief of the Digestive
Disease Institute
Cleveland Clinic, Cleveland

Both studies in this month’s The Regueiro Report are about interleukin inhibitors: risankizumab (Skyrizi, AbbVie), which inhibits the activity of IL-23 subunit p19, and ustekinumab (Stelara, Janssen), which inhibits IL-12/-23 subunit p40.

Another commonality between the studies is that both medications appear efficacious and safe during the